January 21, 2014

Bayer issues EUR 2 billion of bonds

Transaction comprises two-year floating-rate tranche and two EUR 750 million fixed-rate bonds with maturities of four and seven years
Leverkusen, January 21, 2014 - Bayer is taking advantage of currently low
interest rates to raise debt capital on favorable terms. The Group today
successfully issued three Eurobonds with a combined volume of EUR 2 billion.
The proceeds will be used for general corporate purposes and possible

All the tranches were placed on attractive terms. The EUR 500 million two-year
floating-rate Eurobond was issued at an interest rate of 22 basis points over
three-month Euribor. The EUR 750 million four-year fixed-rate Eurobond carries
a coupon of 1.125%, and the EUR 750 million seven-year fixed-rate Eurobond
carries a coupon of 1.875%. The issuances met with exceptionally high demand on
the capital market and the order book was over 4 times oversubscribed.

Said Werner Baumann, CFO of Bayer AG: "The successful placement of these
benchmark bonds confirms Bayer's high standing on the capital market. We have
used our strong position as an issuer and the positive market environment to
improve our debt and liquidity structure."

Bank of America Merrill Lynch, Barclays, Commerzbank and Société Générale
arranged the transaction as active bookrunners. Credit Suisse, Morgan Stanley
and UBS are passive members of the consortium.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the fields of health
care, agriculture and high-tech materials. As an innovation company, it sets
trends in research-intensive areas. Bayer's products and services are designed
to benefit people and improve their quality of life. At the same time, the
Group aims to create value through innovation, growth and high earning power.
Bayer is committed to the principles of sustainable development and to its
social and ethical responsibilities as a corporate citizen. In fiscal 2012, the
Group employed 110,000 people and had sales of ?39.7 billion. Capital
expenditures amounted to ?1.9 billion, R&D expenses to ?3.0 billion. For more
information, go to www.bayer.com.

Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports which are available on the
Bayer website at www.bayer.com. The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or